Phathom Q1 net loss $37.8M, on track to resubmit Erosive GERD NDA this quarter

Phathom Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.89

Net loss $37.8M vs $40.7M YoY; operating expenses 36% lower than prior quarter due to cost controls after launch delay.
Cash $129.6M at Mar 31, 2023; additional $100M term loan available, $175M upon FDA approval of VOQUEZNA for Erosive GERD.
On track to resubmit Erosive GERD NDA this quarter; potential FDA approval and U.S. launch for Erosive GERD and H. pylori in Q4 2023.
Ph3 PHALCON-NERD-301 trial met primary endpoint; regulatory submission for Non-Erosive GERD expected H2 2023.
Coverage secured for 60% of commercial lives for VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income $37.8 million.

Period: the first quarter ended March 31, 2023
Net income: $37.8 million
Result: reported results

Exact text from the filing

Net loss for the first quarter ended March 31, 2023 was $37.8 million, compared to $40.7 million for first quarter 2022.

View on SEC.gov

Browse all earnings releases →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-140078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.